Catalent (NYSE:CTLT) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Catalent (NYSE:CTLT) in a research report released on Tuesday morning. The brokerage issued a sell rating on the stock.

A number of other analysts also recently issued reports on CTLT. Royal Bank of Canada reiterated a sector perform rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday, February 20th. Stephens reiterated an equal weight rating and issued a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. UBS Group restated a neutral rating and set a $63.50 price target (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Finally, Barclays lifted their price objective on Catalent from $45.00 to $47.00 and gave the stock an equal weight rating in a research note on Thursday, January 25th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Catalent presently has an average rating of Hold and a consensus price target of $53.14.

Catalent Trading Down 0.6 %

Shares of Catalent stock opened at $54.65 on Tuesday. The company has a market capitalization of $9.89 billion, a P/E ratio of -8.96, a P/E/G ratio of 6.63 and a beta of 1.18. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. The company has a fifty day moving average of $56.05 and a 200 day moving average of $50.58. Catalent has a fifty-two week low of $31.80 and a fifty-two week high of $60.20.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.36). The business had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. On average, sell-side analysts anticipate that Catalent will post 0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Catalent

Several institutional investors have recently made changes to their positions in CTLT. Nomura Holdings Inc. raised its position in Catalent by 149.4% in the 4th quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock worth $516,126,000 after purchasing an additional 6,881,914 shares during the period. Norges Bank bought a new stake in shares of Catalent during the 4th quarter worth approximately $116,021,000. Cadian Capital Management LP boosted its holdings in Catalent by 91.0% during the 3rd quarter. Cadian Capital Management LP now owns 5,304,784 shares of the company’s stock valued at $241,527,000 after acquiring an additional 2,526,750 shares during the period. Barclays PLC grew its position in Catalent by 41.7% in the 3rd quarter. Barclays PLC now owns 4,797,718 shares of the company’s stock valued at $218,440,000 after acquiring an additional 1,412,058 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Catalent by 65.9% in the third quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company’s stock worth $158,601,000 after purchasing an additional 1,384,313 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.